Description
A combination vial of 20mg retatrutide and 40mg tirzepatide (60mg total), pairing the triple GIP/GLP-1/glucagon agonist with the dual GIP/GLP-1 agonist. It is used in research on combined incretin-receptor agonism.
10 vials per box. Strengths are per vial; prices are per box.
For research use only. Not for human or veterinary use.





